Why Concert Pharmaceuticals Stock Is Tanking Today
Shares fall hard after a late-stage trial comes up short.
Concert Pharmaceuticals
CNCE
CNCE
$6.21
$0.32
5.4%
BATS BZX Real Time Price as of October 15, 2019, 4:00 p.m. EDT
View Interactive CNCE Charts
CONCERT PHARMACEUT
News & Analysis: Concert Pharmaceuticals
Concert Pharmaceuticals, Inc. (CNCE) Q2 2019 Earnings Call Transcript
CNCE earnings call for the period ending June 30,2019.
Concert Pharmaceuticals, Inc. (CNCE) Q1 2019 Earnings Call Transcript
CNCE earnings call for the period ending March 31, 2019.
Concert Pharmaceuticals, Inc. (CNCE) Q4 2018 Earnings Conference Call Transcript
CNCE earnings call for the period ending December 31, 2018.
Why Concert Pharmaceuticals, Inc. Is Singing the Blues Today
Bad news trumps good news for the biotech.
Why General Electric, Concert Pharmaceuticals, and NVR Jumped Today
Even on a quiet day on Wall Street, these stocks posted gains. Find out why.
3 Biotech Stocks to Buy in March
Why Spark Therapeutics, Albany Molecular Research, and Concert Pharmaceuticals could be great biotech stocks to buy as spring approaches.
Why Concert Pharmaceuticals Stock Is Soaring Today
The pharma cut a deal with Vertex for the experimental experimental cystic fibrosis drug CTP-656.
Vertex Turns Up the Heat on Cystic Fibrosis Challengers
With two new correctors entering clinical development, Vertex is about to leave Galapagos and Concert in the dust.
Shareholders Breathe Easier As Concert Pharmaceuticals Rockets Higher by 23%
Concert Pharmaceuticals' phase 1 data dazzles when put side by side with a major competitors' FDA-approved cystic fibrosis drug,
